Navigation Links
Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
Date:4/17/2009

SAN DIEGO, April 17 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will report first quarter 2009 financial results on Thursday, April 23, 2009, after the U.S. financial markets close.

Anadys will hold a conference call and webcast on Thursday, April 23, 2009 at 5:00 p.m. Eastern Daylight Time to discuss its first quarter 2009 financial results and highlights and to provide an update on its development programs, including a review of the ANA598 antiviral data that will be presented that day at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL). A live webcast of the call will be available online at www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 85383527. The webcast and telephone replay will be available through May 7, 2009.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral inducer of endogenous interferons that acts via the TLR7 pathway. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines in the areas of hepatitis C and oncology. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2008. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
2. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
3. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
4. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
5. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
6. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
7. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
8. Anadys Pharmaceuticals to Report Third Quarter 2008 Financial Results
9. Anadys Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
10. Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
11. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017   VWR ... of product and service solutions to laboratory ... has acquired EPL Archives, Inc., an international ... the entire regulated product research, development and ... storage and ancillary services. EPL Archives is ...
(Date:3/22/2017)... San Diego, Calif. (PRWEB) , ... March 21, ... ... Frame on Kickstarter , more than tripling its goal and raising over ... and low-maintenance vertical garden that grows nutritious veggies & herbs fast, easy, and ...
(Date:3/22/2017)... , ... March 22, 2017 , ... March 22, 2017...Council ... for another green revolution, one that utilizes technological innovation in smart, sustainable ways. Humans ... of life such as aesthetics and environmental stability. This paper is the first in ...
(Date:3/20/2017)... ... March 20, 2017 , ... SSCI and Whitehouse Laboratories, divisions of Albany Molecular ... Sponsored by the Parenteral Drug Association (PDA), the New York Interphex Show will ... in attendance and more than 625 exhibitors, the educational and networking opportunities are extremely ...
Breaking Biology Technology:
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
(Date:2/24/2017)...  EyeLock LLC, a leader of iris-based identity ... biometric solution on the latest Qualcomm® Snapdragon™ 835 ... World Congress 2017 (February 27 – March ... 3, Stand 3E10. The Snapdragon ... platform—a combination of hardware, software and biometrics ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 ... Family of Companies (Avamere Health Services, Infinity Rehab, Signature ... research study that will apply the power of IBM ... living and health centers. By analyzing data streaming from ... insights into physical and environmental conditions, and obtain deeper ...
Breaking Biology News(10 mins):